News

Physician adherence to guidelines for screening for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc) was found to be poor in Australia, according to a multi-center research study that evaluated the percentage of doctors who adhere to recommended SSc guidelines. The study, “Epidemiology and disease…

Corbus Pharmaceuticals will present results showing that Resunab (JBT-101), the company’s cannabis-derived treatment for systemic sclerosis (SSc), can trigger specific molecular pathways which resolve inflammation and halt fibrosis. The data will be presented by Michael L. Whitfield, PhD, a molecular biology professor at Dartmouth and scientific founder of Celdara Medical,…

A new study from France found that treatment with intravenous immunoglobulins (IVIG), known to have anti-fibrotic activity, is effective in improving muscle, joint and digestive tract function in patients with systemic sclerosis (SSc). The study, “Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients…

Patients with pulmonary arterial hypertension (PAH) linked to scleroderma have worse outcomes than those with idiopathic PAH, with survival times of less than half of iPAH patients. The difference is likely tied to numerous factors, but older age and a poor transfer of gas (abnormal oxygen-carbon monoxide transfer) in the…

People with systemic sclerosis (SSc) frequently experience foot problems, but foot assessment and healthcare for SSc patients are still inadequate, according to new research. The study, “Biomechanical Podiatric Evaluation In An Italian Cohort Of Patients With Systemic Sclerosis: A Pilot Study,” was published in the European Journal of…

Patients with severe forms of systemic sclerosis (SSc) may frequently develop fingernail abnormalities, with such changes affecting four out of five SSc patients in a small study in France. The study, “Nail Involvement in Systemic Sclerosis,” appeared in the Journal of the American Academy of Dermatology (JAAD). “Whereas skin abnormalities have been…

A large study following patients in the early stages of diffuse cutaneous scleroderma showed that immunosuppressants offered only a negligible benefit for those who took them, compared to those who didn’t. Since immunosuppressants produced numerically larger reductions in skin symptoms, the findings may support patients using such drugs from the onset of their…

Treating endothelial cells obtained from scleroderma patients with an enzyme called khloto effectively improves their function, according to a study published in the journal Arthritis Research and Therapy.

Researchers have found links between several heavy metals and scleroderma, a discovery that prompted them to encourage doctors to check whether their patients had occupational exposure to heavy metals. Interestingly, some metals were associated more with male scleroderma patients and some with females. The study, “Systemic sclerosis and…

The U.S. Food and Drug Administration (FDA) has granted Cytori Therapeutics Small Business status for fiscal year 2017, which means Cytori will pay reduced fees for regulatory filings that may arise from initiatives like the Phase 3 trial of its Habeo Cell Therapy for hand dysfunction and Raynaud’s phenomenon associated with scleroderma.